Prilenia's New Chapter with Key Leadership Appointments
NAARDEN, The Netherlands & WALTHAM, Mass. -- Prilenia Therapeutics B.V., a forward-thinking biotechnology company focused on creating treatments for neurodegenerative diseases, has made important progress by welcoming two highly experienced professionals to its executive leadership team. Rob Lauzen is appointed as the Chief Financial Officer (CFO), while Jason Marks, J.D., steps in as the Chief Legal Officer (CLO). These key appointments underscore Prilenia’s strong commitment to advancing its mission, especially with the upcoming commercialization of their therapeutic agent, pridopidine.
A Transformative Moment for Prilenia
According to Dr. Michael R. Hayden, CEO of Prilenia, “This is a transformational time for Prilenia.” He expresses confidence in Lauzen and Marks due to their impressive skills and track record, which are likely to propel Prilenia’s initiatives. Dr. Hayden believes their expertise will greatly contribute to successfully bringing pridopidine to patients while ensuring effective strategy execution.
Rob Lauzen Steps In as CFO
Rob Lauzen adds nearly a decade of extensive financial and strategic experience in the life sciences field. His previous position as Vice President of Investor Relations and Head of Financial Planning & Analysis at Dyne Therapeutics has equipped him with the tools to manage Prilenia’s capital strategies. Lauzen’s impressive history includes advising on complex financial deals while at Morgan Stanley, where he played a key role in numerous successful mergers and acquisitions, totaling over $185 billion. He holds a degree in Engineering Sciences from Dartmouth College, which enhances his analytical capabilities.
Sharing his excitement about joining Prilenia, Lauzen stated, “I am thrilled to join Prilenia at this pivotal time in the Company’s development.” He pointed out the unique opportunity to aid in the advancement of pridopidine for Huntington’s disease patients and others in need.
Jason Marks: Bringing Legal Expertise to the Table
With more than 20 years of legal experience, Jason Marks joins Prilenia to strengthen its compliance and legal functions. His notable career covers various regions, including significant roles at Teva, where he focused on Global Transactions and Finance. Marks has held the positions of CLO, CCO, and Corporate Secretary at various publicly listed companies, showcasing a comprehensive responsibility in legal oversight, governance, and compliance. He graduated from the University of Chicago and earned his J.D. from George Washington University Law School with honors.
Marks’ vision for Prilenia is expressed clearly: “I am honored to partner with a team of this caliber.” He emphasizes the company's commitment to addressing the global unmet needs related to Huntington’s disease, highlighting its ambition to create a strategic and efficient organization to effectively support its mission.
About Prilenia Therapeutics
Founded in 2018, Prilenia Therapeutics is dedicated to creating innovative treatments that aim to slow down the progression of neurodegenerative diseases like Huntington's and ALS. The company is supported by a consortium of distinguished investors, ensuring strong financial and operational backing.
Prilenia’s commitment to advancing medical solutions marks a significant development in the biotech field, as it consistently pursues excellence in research and development within the life sciences sector.
Frequently Asked Questions
Who has been appointed as CFO of Prilenia?
Rob Lauzen has been named the Chief Financial Officer of Prilenia Therapeutics.
What is the focus of Prilenia Therapeutics?
Prilenia aims to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders.
Where is Prilenia Therapeutics based?
Prilenia Therapeutics is incorporated in the Netherlands.
What are the backgrounds of the new executives at Prilenia?
Rob Lauzen has significant experience in finance within the life sciences sector, while Jason Marks brings extensive legal expertise from both in-house and external counsel roles.
What mission does Prilenia Therapeutics aim to accomplish?
The mission is to address significant unmet medical needs associated with Huntington’s disease and ALS by developing effective therapeutics.
